Profile data is unavailable for this security.
About the company
Lyell Immunopharma, Inc. is a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with hematologic malignancies and solid tumors. The Company’s product candidates include LYL314 and LYL273. Its LYL314, which is in Phase I/II clinical development, is a dual-targeting CD19/CD20 CAR T-cell product candidate designed to increase complete response rates and prolong the duration of response as compared to the approved CD19-targeted CAR T-cell therapies and is under evaluation trial for the treatment of patients with relapsed and/or refractory large B-cell lymphoma. The Company has acquired the global rights to LYL273 (formerly GCC19CART), a novel autologous guanylyl cyclase-C (GCC)-targeted CAR T-cell product candidate for the treatment of metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
- Revenue in USD (TTM)41.00k
- Net income in USD-325.66m
- Incorporated2018
- Employees300.00
- LocationLyell Immunopharma Inc201 Haskins Way, Suite 301SOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (650) 695-0677
- Fax+1 (302) 531-3150
- Websitehttps://lyell.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tectonic Therapeutic Inc | 0.00 | -74.15m | 458.06m | 60.00 | -- | 1.82 | -- | -- | -4.04 | -4.04 | 0.00 | 13.41 | 0.00 | -- | -- | 0.00 | -35.83 | -- | -37.77 | -- | -- | -- | -- | -- | -- | -- | 0.0015 | -- | -- | -- | -27.89 | -- | -- | -- |
| Kyverna Therapeutics Inc | 0.00 | -160.99m | 458.16m | 129.00 | -- | 2.31 | -- | -- | -3.72 | -3.72 | 0.00 | 3.47 | 0.00 | -- | -- | 0.00 | -61.17 | -- | -69.77 | -- | -- | -- | -- | -- | -- | -- | 0.0013 | -- | -- | -- | -111.17 | -- | -- | -- |
| Vanda Pharmaceuticals Inc. | 216.11m | -220.47m | 463.41m | 533.00 | -- | 1.42 | -- | 2.14 | -3.74 | -3.74 | 3.67 | 5.54 | 0.3774 | 7.29 | 4.25 | 405,450.30 | -38.51 | -6.49 | -48.99 | -7.64 | 93.96 | 92.12 | -102.02 | -17.46 | 2.38 | -- | 0.0224 | -- | 8.72 | -2.73 | -1,066.53 | -- | -11.08 | -- |
| Solid Biosciences Inc | 0.00 | -167.14m | 464.35m | 100.00 | -- | 2.13 | -- | -- | -2.49 | -2.49 | 0.00 | 2.80 | 0.00 | -- | -- | 0.00 | -68.82 | -47.92 | -78.37 | -53.98 | -- | -- | -- | -2,151.47 | -- | -- | 0.0013 | -- | -- | -- | -29.87 | -- | -31.66 | -- |
| Adlai Nortye Ltd (ADR) | 0.00 | -42.59m | 468.09m | 123.00 | -- | 37.31 | -- | -- | -1.14 | -1.14 | 0.00 | 0.2147 | 0.00 | -- | -- | 0.00 | -47.40 | -- | -138.41 | -- | -- | -- | -- | -- | -- | -26.36 | 0.8491 | -- | -- | -- | 52.51 | -- | -- | -- |
| Altimmune Inc | 20.00k | -83.92m | 469.39m | 59.00 | -- | 2.14 | -- | 23,469.39 | -1.07 | -1.07 | 0.0003 | 1.94 | 0.0001 | -- | 0.0314 | 338.98 | -45.82 | -42.36 | -48.64 | -45.46 | -- | -- | -419,575.00 | -3,193.88 | -- | -- | 0.0722 | -- | -95.31 | -67.83 | -7.48 | -- | -- | -- |
| Climb Bio Inc | 0.00 | -50.75m | 483.43m | 17.00 | -- | 2.73 | -- | -- | -0.7507 | -0.7507 | 0.00 | 2.60 | 0.00 | -- | -- | 0.00 | -25.09 | -39.53 | -25.62 | -41.05 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -110.42 | -- | -- | -- |
| Lyell Immunopharma Inc | 41.00k | -325.66m | 495.62m | 300.00 | -- | 1.37 | -- | 12,088.33 | -22.26 | -22.26 | 0.0027 | 17.06 | 0.00008 | -- | -- | 136.67 | -63.41 | -28.62 | -67.72 | -30.08 | -- | -- | -794,292.70 | -1,176.84 | -- | -- | 0.00 | -- | -53.08 | -37.83 | -46.18 | -- | 14.67 | -- |
| ADC Therapeutics SA | 75.21m | -166.94m | 501.70m | 263.00 | -- | -- | -- | 6.67 | -1.51 | -1.51 | 0.6852 | -2.11 | 0.2355 | 0.3207 | 3.20 | 285,965.80 | -52.26 | -45.95 | -65.58 | -53.58 | 92.73 | -- | -221.97 | -263.96 | 4.34 | -2.91 | 2.10 | -- | 1.84 | 97.79 | 34.25 | -- | -16.59 | -- |
| Prothena Corporation PLC | 9.68m | -244.09m | 503.88m | 67.00 | -- | 1.80 | -- | 52.03 | -4.53 | -4.53 | 0.1799 | 5.21 | 0.0222 | -- | -- | 144,537.30 | -55.86 | -19.16 | -62.22 | -20.73 | -- | -- | -2,520.57 | -114.82 | -- | -- | 0.00 | -- | -92.84 | 62.56 | -99.57 | -- | -6.78 | -- |
| Neumora Therapeutics Inc | 0.00 | -236.30m | 504.27m | 95.00 | -- | 3.75 | -- | -- | -1.46 | -1.46 | 0.00 | 0.8161 | 0.00 | -- | -- | 0.00 | -89.11 | -55.45 | -99.96 | -58.77 | -- | -- | -- | -- | -- | -- | 0.1289 | -- | -- | -- | -3.33 | -- | -- | -- |
| Contineum Therapeutics Inc | 0.00 | -59.39m | 515.07m | 41.00 | -- | 2.28 | -- | -- | -2.26 | -2.26 | 0.00 | 6.18 | 0.00 | -- | -- | 0.00 | -29.19 | -- | -30.09 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -285.99 | -- | -- | -- |
| Lexeo Therapeutics Inc | 0.00 | -104.97m | 516.02m | 72.00 | -- | 3.21 | -- | -- | -2.70 | -2.70 | 0.00 | 2.20 | 0.00 | -- | -- | 0.00 | -66.08 | -- | -76.72 | -- | -- | -- | -- | -- | -- | -- | 0.0084 | -- | -- | -- | -48.11 | -- | -- | -- |
| Rocket Pharmaceuticals Inc | 0.00 | -223.12m | 521.13m | 202.00 | -- | 1.88 | -- | -- | -2.01 | -2.01 | 0.00 | 2.56 | 0.00 | -- | -- | 0.00 | -52.00 | -42.96 | -56.68 | -46.18 | -- | -- | -- | -- | -- | -- | 0.0713 | -- | -- | -- | 13.77 | -- | -56.75 | -- |
| Fulcrum Therapeutics Inc | 0.00 | -74.88m | 524.14m | 55.00 | -- | 1.50 | -- | -- | -1.18 | -1.18 | 0.00 | 5.24 | 0.00 | -- | -- | 0.00 | -23.89 | -30.35 | -24.84 | -32.48 | -- | -- | -- | -344.07 | -- | -- | 0.00 | -- | -100.00 | -- | -669.97 | -- | -25.21 | -- |
Data as of Mar 03 2026. Currency figures normalised to Lyell Immunopharma Inc's reporting currency: US Dollar USD
11.67%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 734.34k | 3.46% |
| Almitas Capital LLCas of 31 Dec 2025 | 577.81k | 2.72% |
| Citadel Advisors LLCas of 31 Dec 2025 | 317.03k | 1.49% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 167.02k | 0.79% |
| Geode Capital Management LLCas of 31 Dec 2025 | 163.00k | 0.77% |
| Susquehanna Financial Group LLLPas of 31 Dec 2025 | 151.02k | 0.71% |
| Invesco Capital Management LLCas of 31 Dec 2025 | 98.65k | 0.46% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Dec 2025 | 96.68k | 0.46% |
| MIC Capital Management UK LLPas of 31 Dec 2025 | 87.03k | 0.41% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 86.93k | 0.41% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
